Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update

Reva Schneider1, Ayman Barakat1, John Pippen1,2,3, Cynthia Osborne1,2,3 1Medical Oncology, Baylor-Sammons Cancer Center, 2Texas Oncology PA, 3US Oncology, Dallas, TX, USA Abstract: Estrogen and its metabolites play a significant role in the proliferation of hormone receptor-positive breast cancer. I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Schneider RE, Barakat AY, Pippen JE, Osborne CR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b517bf99f4fc4d218a09d68e37c7adb0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b517bf99f4fc4d218a09d68e37c7adb0
record_format	dspace
spelling	oai:doaj.org-article:b517bf99f4fc4d218a09d68e37c7adb02021-12-02T06:38:16ZAromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update1179-1314https://doaj.org/article/b517bf99f4fc4d218a09d68e37c7adb02011-10-01T00:00:00Zhttp://www.dovepress.com/aromatase-inhibitors-in-the-treatment-of-breast-cancer-in-post-menopau-a8406https://doaj.org/toc/1179-1314Reva Schneider1, Ayman Barakat1, John Pippen1,2,3, Cynthia Osborne1,2,3 1Medical Oncology, Baylor-Sammons Cancer Center, 2Texas Oncology PA, 3US Oncology, Dallas, TX, USA Abstract: Estrogen and its metabolites play a significant role in the proliferation of hormone receptor-positive breast cancer. In postmenopausal women, aromatase inhibitors can significantly reduce estrogen levels by blocking enzyme-mediated estrogen synthesis within tissues. Third-generation aromatase inhibitors have now surpassed tamoxifen as first-line therapy for postmenopausal women with metastatic, hormone receptor-positive, breast cancer, showing improved response rates and time to progression. Aromatase inhibitors have shown incremental improvements in disease-free survival, lower local recurrence rates, lower metastatic recurrence rates, and a lower incidence of contralateral breast cancer over tamoxifen when used in the adjuvant setting. Aromatase inhibitors are recommended to be used as adjuvant therapy within the first 5 years of hormonal therapy and may be used either upfront for 5 years or sequenced with tamoxifen. No superiority of one aromatase inhibitor over another has yet been shown. The side effect profiles of aromatase inhibitors have some key differences compared with tamoxifen. These differences may influence treatment choices as well as impact compliance. Keywords: aromatase inhibitor, breast cancer, postmenopausal, hormonal therapySchneider REBarakat AYPippen JEOsborne CRDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2011, Iss default, Pp 113-125 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Schneider RE Barakat AY Pippen JE Osborne CR Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
description	Reva Schneider1, Ayman Barakat1, John Pippen1,2,3, Cynthia Osborne1,2,3 1Medical Oncology, Baylor-Sammons Cancer Center, 2Texas Oncology PA, 3US Oncology, Dallas, TX, USA Abstract: Estrogen and its metabolites play a significant role in the proliferation of hormone receptor-positive breast cancer. In postmenopausal women, aromatase inhibitors can significantly reduce estrogen levels by blocking enzyme-mediated estrogen synthesis within tissues. Third-generation aromatase inhibitors have now surpassed tamoxifen as first-line therapy for postmenopausal women with metastatic, hormone receptor-positive, breast cancer, showing improved response rates and time to progression. Aromatase inhibitors have shown incremental improvements in disease-free survival, lower local recurrence rates, lower metastatic recurrence rates, and a lower incidence of contralateral breast cancer over tamoxifen when used in the adjuvant setting. Aromatase inhibitors are recommended to be used as adjuvant therapy within the first 5 years of hormonal therapy and may be used either upfront for 5 years or sequenced with tamoxifen. No superiority of one aromatase inhibitor over another has yet been shown. The side effect profiles of aromatase inhibitors have some key differences compared with tamoxifen. These differences may influence treatment choices as well as impact compliance. Keywords: aromatase inhibitor, breast cancer, postmenopausal, hormonal therapy
format	article
author	Schneider RE Barakat AY Pippen JE Osborne CR
author_facet	Schneider RE Barakat AY Pippen JE Osborne CR
author_sort	Schneider RE
title	Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
title_short	Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
title_full	Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
title_fullStr	Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
title_full_unstemmed	Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
title_sort	aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/b517bf99f4fc4d218a09d68e37c7adb0
work_keys_str_mv	AT schneiderre aromataseinhibitorsinthetreatmentofbreastcancerinpostmenopausalfemalepatientsanupdate AT barakatay aromataseinhibitorsinthetreatmentofbreastcancerinpostmenopausalfemalepatientsanupdate AT pippenje aromataseinhibitorsinthetreatmentofbreastcancerinpostmenopausalfemalepatientsanupdate AT osbornecr aromataseinhibitorsinthetreatmentofbreastcancerinpostmenopausalfemalepatientsanupdate
_version_	1718399834182909952

Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update

Ejemplares similares